Aky MD, LLC
Aky MD, LLC was paid $42.29M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 38% of everything it billed.
33Billing provider infoAKY MD, LLC
MOORE, OK 73160
MOORE, OK 73160
33aNPI1063846699assigned 08/30/2013
33bProvider typeRegistered Dietitian
28Total paid$42.29M
24GClaims868,528
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Registered Dietitian providers in Oklahoma
Rank by total paid#1 of 26
Median peer was paid$254K
This provider vs. median167×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 66,308 | $2.95M | |
| 2019 | 72,731 | $3.69M | |
| 2020 | 89,668 | $3.79M | |
| 2021 | 125,674 | $5.79M | |
| 2022 | 166,034 | $8.35M | |
| 2023 | 191,669 | $9.66M | |
| 2024incomplete | 156,444 | $8.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 38% | 155,918 | 151,278 | $16.09M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22% | 126,658 | 123,069 | $9.17M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.9% | 32,611 | 32,602 | $2.93M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.7% | 33,018 | 32,581 | $2.83M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 5.4% | 83,459 | 83,295 | $2.28M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.5% | 16,977 | 16,968 | $1.49M |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.5% | 33,883 | 33,854 | $1.07M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.2% | 24,403 | 23,950 | $941K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 18,704 | 18,583 | $480K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 5,492 | 5,471 | $448K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.0% | 4,515 | 4,515 | $432K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,728 | 2,034 | $419K |
75 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 27,030 | $389K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,704 | $356K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 5,598 | $353K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,410 | $348K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,417 | $326K |
| 99381 | <1% | 2,575 | $248K | |
| 87428 | <1% | 5,728 | $220K | |
| 99051 | <1% | 29,723 | $195K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,290 | $184K |
| 90474 | <1% | 10,189 | $184K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 18,621 | $156K |
| 96161 | <1% | 28,436 | $123K | |
| 96127 | <1% | 29,691 | $121K | |
| 87634 | <1% | 1,391 | $85K | |
| 83655 | <1% | 6,232 | $67K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,811 | $66K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,430 | $64K |
| 87807 | <1% | 3,571 | $41K | |
| 99383 | <1% | 386 | $40K | |
| 99173 | <1% | 9,210 | $23K | |
| 85018 | <1% | 7,891 | $17K | |
| 99188 | <1% | 1,557 | $16K | |
| 92523 | <1% | 69 | $14K | |
| 0071A | <1% | 349 | $13K | |
| 98966 | <1% | 784 | $9K | |
| 99382 | <1% | 88 | $9K | |
| 97166 | <1% | 82 | $7K | |
| 0072A | <1% | 171 | $6K | |
| 97162 | <1% | 57 | $5K | |
| 99384 | <1% | 27 | $3K | |
| 0001A | <1% | 57 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 111 | $2K |
| 99050 | <1% | 77 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 86 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 888 | $1K |
| 94664 | <1% | 59 | $842.19 | |
| 96380 | <1% | 44 | $778.12 | |
| 99441 | <1% | 15 | $737.85 | |
| 98967 | <1% | 33 | $716.43 | |
| 0002A | <1% | 12 | $480.00 | |
| 80061 | Lipid panel | <1% | 36 | $423.44 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 132 | $203.91 |
| 90686 | <1% | 8,057 | $192.27 | |
| 90674 | <1% | 2,528 | $128.10 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 83 | $113.98 |
| 96160 | <1% | 19,051 | $46.70 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 20 | $25.50 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 29 | $17.88 |
| 36416 | <1% | 17 | $8.01 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 82 | $4.36 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12 | $1.69 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 12 | $1.26 |
| 90661 | <1% | 1,149 | $0.64 | |
| 90670 | <1% | 20,750 | $0.58 | |
| 90681 | <1% | 7,082 | $0.34 | |
| 90633 | <1% | 8,758 | $0.27 | |
| 90697 | <1% | 4,311 | $0.12 | |
| 90651 | <1% | 2,105 | $0.09 | |
| 90734 | <1% | 1,190 | $0.03 | |
| 90620 | <1% | 76 | $0.02 | |
| 90648 | 0% | 14,672 | $0.00 | |
| 90700 | 0% | 1,043 | $0.00 | |
| 90707 | 0% | 1,142 | $0.00 | |
| 90710 | 0% | 1,948 | $0.00 | |
| 90715 | 0% | 601 | $0.00 | |
| 91300 | 0% | 184 | $0.00 | |
| 90672 | 0% | 46 | $0.00 | |
| 90716 | 0% | 1,209 | $0.00 | |
| 90723 | 0% | 10,980 | $0.00 | |
| 91307 | 0% | 690 | $0.00 | |
| 90696 | 0% | 1,074 | $0.00 | |
| 90660 | 0% | 30 | $0.00 | |
| 90381 | 0% | 29 | $0.00 | |
| 90677 | 0% | 120 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENTHORN, LESLEY (CREDENTIALING)
Parent organizationAKY, MD LLC
| Provider | Location | Paid |
|---|---|---|
| Your Health LLC | Moore, OK | $1.59M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.